5PSQ-076
L04- IMMUNOSUPPRESSANTS

PATIENTS' SATISFACTION AFTER CHANGING FROM 150MG TO 300MG SECUKINUMAB PEN PRESENTATION

P. Castro[1], V. Charques[1], A. Retamero[1], S. Mendiola[1], A. Figueras[1], J. Serrais[1], J.Martínez[1], D. Ferrandez[1]
[1] Pharmacy Department. Hospital Universitari d'Igualada, Barcelona, Spain

BACKGROUND AND IMPORTANCE

Secukinumab is an anti-interleukin-17 drug used for psoriasis, psoriatic arthritis or spondyloarthritis. Recently, our hospital changed from 150mg to 300mg secukinumab pen presentation in order to simplify treatment and facilitate administration. However, as patients often have other expectations, desires and priorities evaluating the degree of satisfaction allows us to identify deficiencies and causes of dissatisfaction.

AIM AND OBJECTIVES

To determine patients' satisfaction after changing from 150mg to 300mg secukinumab pen presentation.

MATERIALS AND METHODS

Retrospective study carried out in a regional hospital.
Patients on treatment with secukinumab 2x150mg/month who changed presentation to 300mg/month during November-December 2021 were included.

Patients who hadn´t taken both presentations for at least 4 months and patients impossible to locate were excluded.
Those who gave their verbal consent underwent a telephone survey.

Qualitative variables were expressed as frequency and percentage and quantitative ones as mean and standard deviation. Statistical analysis was performed with Excel (v.12.0).

VARIABLES COLLECTED
Demographic data
Drug indication
Treatment duration
Self-administration
Pain measured with VAS (Visual Analogue Scale) with both presentations
Presence of administration site reactions with both presentations
Satisfaction with pen change measured from 0 to 10 (0 minimum-10 maximum)
300mg pen discontinuation and reason

RESULTS

24 (72,2%) PATIENTS INCLUDED

Nine (42.9%) women; age: 49 (13.9) years old

Treatment duration: 38.7 (22.6) months

Patients who self-administered medication: 23 (95.8%)

Two (8.3%) had to discontinue the 300mg presentation due to severe pain during administration



150 MG PRESENTATION	300 MG PRESENTATION
VAS 1.8 (1.2)	VAS 2.2 (1.9)
2 (8.3%) patients reported having bruises at the injection site	3 (12.5%) reported having suffered swelling that reverted spontaneously

Regarding change satisfaction: 21 (87.5%) referred to the change as satisfactory,
2 (8.3%) as not satisfactory and 1 (4.1%) as indifferent, with the average satisfaction being 8.0 (2.2).

CONCLUSIONS

- Changing from 150mg to 300mg secukinumab pen presentation was considered satisfactory for 87.5% of patients.
- Two patients suffered greater pain during administration, leading to a return to the previous presentation.
- It would be advisable to carry out additional follow-up in order to detect possible reactions at the administration site or greater pain after the change of presentation.